Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Small Cell Lung Carcinoma × talazoparib × Clear all

Phase

Phase 1 3 Phase 2 1

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 13 Triple Negative Breast Neoplasms 7 Prostatic Neoplasms 6 Neoplasms 5 Neoplasm Metastasis 4 Ovarian Neoplasms 3 Endometrial Neoplasms 2 Stomach Neoplasms 1 Small Cell Lung Carcinoma 1 Recurrence 1 Prostate Cancer Metastatic 1 Premenopausal HR+/HER2- Metastatic Breast Cancer 1 Pheochromocytoma 1 Pathologic Complete Response 1 Paraganglioma 1 Pancreatic Neoplasms 1 Multiple Myeloma 1 Lymphoma, Non-Hodgkin 1 Hereditary Sensory and Autonomic Neuropathies 1 Hemangiosarcoma 1 Glioma 1 Glioblastoma 1 Gastrointestinal Neoplasms 1 Fallopian Tube Neoplasms 1 Colorectal Neoplasms 1 Carcinoma, Transitional Cell 1 Carcinoma, Squamous Cell 1 Carcinoma, Non-Small-Cell Lung 1 Breast Adenocarcinoma 1 Advanced Breast Cancer 1

Interventions

Etoposide 70 Carboplatin 60 Cisplatin 40 Topotecan 26 durvalumab 25 atezolizumab 18 Radiotherapy 18 Irinotecan 18 Paclitaxel 15 Nivolumab 15 apatinib 14 anlotinib 12 Drug Therapy 12 pembrolizumab 9 Platinum 9 toripalimab 8 Bevacizumab 8 Radiosurgery 7 PM 01183 7 Ipilimumab 7 tislelizumab 6 Gemcitabine 6 olaparib 5 amrubicin 5 Temozolomide 5 Sunitinib 5 Pemetrexed 5 Docetaxel 5 Albumin-Bound Paclitaxel 5 irinotecan sucrosofate 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03672773 2025-11-10

TRIO-US L-07

Jonsson Comprehensive Cancer Center

Phase 2 Active not recruiting

Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡